Review



integrin β4  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 133 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/integrin β4/product/Santa Cruz Biotechnology
    Average 93 stars, based on 133 article reviews
    integrin β4 - by Bioz Stars, 2026-04
    93/100 stars

    Images

    1) Product Images from "Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity"

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

    Journal: Science Advances

    doi: 10.1126/sciadv.aeb5894

    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Figure Legend Snippet: ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Techniques Used: Activation Assay, Construct, Expressing, Western Blot, Confocal Microscopy, Incubation, FLAG-tag



    Similar Products

    integrin β4  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/integrin β4/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    integrin β4 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    integrin β4  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc integrin β4
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Integrin β4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/integrin β4/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    integrin β4 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    sc 35678 lats1 sirna human santa cruz biotechnology  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology sc 35678 lats1 sirna human santa cruz biotechnology
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    Sc 35678 Lats1 Sirna Human Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sc 35678 lats1 sirna human santa cruz biotechnology/product/Santa Cruz Biotechnology
    Average 92 stars, based on 1 article reviews
    sc 35678 lats1 sirna human santa cruz biotechnology - by Bioz Stars, 2026-04
    92/100 stars
    		  Buy from Supplier
    β4 integrin  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc β4 integrin
    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of <t>integrin</t> α6, integrin <t>β4,</t> and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].
    β4 Integrin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/β4 integrin/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    β4 integrin - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    anti itgb4 antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti itgb4 antibody
    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and <t>ITGB4</t> expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.
    Anti Itgb4 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti itgb4 antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti itgb4 antibody - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    polyclonal itgb4  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology polyclonal itgb4
    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and <t>ITGB4</t> expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.
    Polyclonal Itgb4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal itgb4/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    polyclonal itgb4 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Journal: Science Advances

    Article Title: Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

    doi: 10.1126/sciadv.aeb5894

    Figure Lengend Snippet: ( A ) The preparation of CAPTURE. ( B and C ) Representative TEM image and dynamic light scattering (DLS) showed NVs of similar shapes and sizes. Scale bars, 200 nm. ( D to I ) OVA-specific expansion and activation of primary mouse T cells: 10 5 OT-I CD8 + T cells per well were coincubated with a variety of NVs (20 μg ml −1 ) (D), including CAPTURE with different constructs of the αCD28 antibody (E) or different type of vesicles (F to I). Following 3 days of coincubation, assessments of T cell expansion (F) and activation (G to I) were conducted. ( J ) Cytotoxicity of OT-I CD8 + T cells against B16-OVA cells post–NVs treatment under various conditions; cells were coincubated at differing effector-target (E:T) ratios for 24 hours. ( K ) After 36 hours of CAP treatment, the induced expression of integrin α6, integrin β4, and v-SNARE in tumor cell NVs was evaluated by Western blot analysis. ( L ) Confocal microscopy images of B16-OVA tumor cells incubated with CAPTURE (20 μg ml −1 ) for 24 hours. Blue: cell nuclei, green: MHC-I, red: Flag tag. Scale bar, 10 μm. (B), (C), (K), and (L) show representative results of two independent experiments with similar results. The data are shown as the mean ± SD from a representative experiment of two to three independent experiments with n = 5 (E, F, and I) and n = 4 (G, H, and J) biologically independent samples. Statistical significance was calculated via one-way ANOVA in (E) and (G) to (I) or two-way ANOVA in (J) with Bonferroni multiple comparisons posttest. Synergy analysis (via the Highest Single Agent model) comparing the B16-OVA-NV(CAP), B16-OVA-NV-αCD28, and CAPTURE groups indicated a significant synergistic effect for CAPTURE [ P = 0.0102 (G), P = 0.0015 (H), and P = 0.0026 (I)].

    Article Snippet: The expression of Integrin α6, Integrin β4, and v-SNARE (all antibodies sourced from Santa Cruz Biotechnology) was analyzed by Western blot.

    Techniques: Activation Assay, Construct, Expressing, Western Blot, Confocal Microscopy, Incubation, FLAG-tag

    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Journal: The Journal of Biological Chemistry

    Article Title: A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesis

    doi: 10.1016/j.jbc.2025.110844

    Figure Lengend Snippet: Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Article Snippet: E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection.

    Techniques: Knockdown, Gene Expression, Transfection, Real-time Polymerase Chain Reaction, Expressing, Comparison, Western Blot

    Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Journal: The Journal of Biological Chemistry

    Article Title: A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesis

    doi: 10.1016/j.jbc.2025.110844

    Figure Lengend Snippet: Effect of ADAMTS18 knockdown on gene expression. A , heatmap representing significant DEGs ( p adj <0.05) common to siAD18-1, siAD18-2, and siAD18-3 at 24 h ( left ) and 96 h ( right ) after transfection. B , Gene Ontology (GO) analysis (g:Profiler) of significant DEGs common to siAD18-1, siAD18-2, and siAD18-3 either at 24 h or 96 h after transfection. C , RT–quantitative PCR analysis of LAMA5 and RBP J expression 24 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). D , RT–quantitative PCR analysis of CXCL1 and ITGB4 expression 96 h after siCTRL, siAD18-1, siAD18-2, and siAD18-3 transfection in HUVEC (mean ± SD, n = 4, lognormal repeated-measures one-way ANOVA with Tukey’s multiple comparison test). E , Western blot (WB) analysis of siCTRL-, siAD18-1-, siAD18-2-, and siAD18-3-transfected HUVEC with anti-ITGB4 antibody (1:250 dilution, sc-514426; Santa Cruz) 96 h after transfection. The siCTRL lane was reordered to the left side of the blot from the right side. F , densitometry analysis (Image Lab) of ITGB4 205 kDa and GAPDH 36 kDa band intensities. The adjusted volume (Int) for ITGB4 was normalized to an adjusted volume (Int) of GAPDH. The data are presented as fold change of siAD18 to siCTRL (mean ± SD, n = 3 using two different HUVEC donors, ordinary one-way ANOVA). Significance is indicated as follows: ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ADAMTS18, A disintegrin and metalloproteinase with thrombospondin motifs 18; DEG, differentially expressed gene; HUVEC, human umbilical vein endothelial cell.

    Article Snippet: After blocking in 5% bovine serum albumin in Tris-buffered saline with Tween-20, membranes were probed with polyclonal ITGB4 (sc-514426; Santa Cruz, 1:250 dilution), GAPDH (14C10; Cell Signaling Technology, 1:1000 dilution), hADAMTS18 (a kind gift from Dr Cathrin Brisken's lab [ISREC], 1:1000 dilution), polyclonal FN (#PA5-29578; Thermo Fisher Scientific, 1:2000 dilution), monoclonal N-terminal FN (#ab270240; Abcam, 1:500 dilution) primary antibodies.

    Techniques: Knockdown, Gene Expression, Transfection, Real-time Polymerase Chain Reaction, Expressing, Comparison, Western Blot